Article
Response of high-risk MDS to azacitidine and lenalidomide is impacted by baseline and acquired mutations in a cluster of three inositide-specific genes.
Leukemia - 1 Sept 2019
Follo Matilde Y, Pellagatti Andrea, Armstrong Richard N, Ratti Stefano, Mongiorgi Sara, De Fanti Sara, Bochicchio Maria Teresa, Russo Domenico, Gobbi Marco, Miglino Maurizio, Parisi Sarah, Martinelli Giovanni, Cavo Michele, Luiselli Donata, McCubrey James A, Suh Pann-Ghill, Manzoli Lucia, Boultwood Jacqueline, Finelli Carlo, Cocco Lucio
Abstract excerpt
Specific myeloid-related and inositide-specific gene mutations can be linked to myelodysplastic syndromes (MDS) pathogenesis and therapy. Here, 44 higher-risk MDS patients were treated with azacitidine and lenalidomide and mutations analyses were performed at baseline and during the therapy. Results were then correlated to clinical outcome, overall survival (OS), leukemia-free-survival (LFS) and response to...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.